Mirzayeh Fashami, F.; Levine, M.; Xie, F.; Blackhouse, G.; Tarride, J.-E.
Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective. Curr. Oncol. 2023, 30, 4688-4699.
https://doi.org/10.3390/curroncol30050354
AMA Style
Mirzayeh Fashami F, Levine M, Xie F, Blackhouse G, Tarride J-E.
Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective. Current Oncology. 2023; 30(5):4688-4699.
https://doi.org/10.3390/curroncol30050354
Chicago/Turabian Style
Mirzayeh Fashami, Fatemeh, Mitchell Levine, Feng Xie, Gordon Blackhouse, and Jean-Eric Tarride.
2023. "Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective" Current Oncology 30, no. 5: 4688-4699.
https://doi.org/10.3390/curroncol30050354
APA Style
Mirzayeh Fashami, F., Levine, M., Xie, F., Blackhouse, G., & Tarride, J.-E.
(2023). Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective. Current Oncology, 30(5), 4688-4699.
https://doi.org/10.3390/curroncol30050354
